$RDY

DR REDDYS LABORATORIES LTD

Dr. Reddy’s Laboratories is an integrated global pharmaceutical company headquartered in Hyderabad, India. It develops, manufactures and markets prescription and over-the-counter medicines, including branded and generic finished products, biosimilars and consumer healthcare products. Its reportable segments are Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others. Global Generics includes finished medicines and biologics, as well as consumer brands in its nicotine replacement therapy business outside the United States. PSAI manufactures and markets active pharmaceutical ingredients and intermediates, provides contract research services, and supplies semi-finished and finished formulations to customers. Others includes Aurigene Oncology, a discovery-stage biotechnology business that works with pharmaceutical and biotechnology companies on drug-discovery collaborations, and a Proprietary Products business that commercializes differentiated formulations. Dr. Reddy’s makes money by selling medicines, ingredients and services, and through milestones and royalties from proprietary products. Its key markets include the United States, India, Russia, other former Soviet Union countries and Europe.

No enriched coverage for $RDY in the last 7 days.

No SEC Form 4 filings for $RDY in the last 30 days.

See all $RDY insider activity →
Low

Weekly Buzz: RDY, LUPIN, SUNPHARMA Score FDA Wins; AGIO, RARE Slash Jobs; CVS Plots Split

Dr. Reddy's (RDY) secured Brazil approval for generic semaglutide and tentative FDA approval for an HIV prevention shot. Lupin (LUPIN.NS) and Sun Pharma (SUNPHARMA.NS) received FDA approvals for generic Firdapse and Ilumya. Agios (AGIO) and Ultragenyx (RARE) announced significant job cuts. CVS (CVS) plans to split into two publicly traded companies. Teva (TEVA) expanded its biosimilars portfolio through a deal with Samsung Bioepis.

Dr.Reddy's Wins Brazil Approval For Generic Ozempic Alternative

Dr. Reddy's Laboratories (RDY) received approval from Brazil's ANVISA for its generic semaglutide injection, a diabetes treatment similar to Novo Nordisk's Ozempic. The product will be marketed in Brazil, a key market with 16.6 million diabetes patients and a $244.6 million semaglutide market. RDY plans to launch the product via a partnership with Ache. RDY stock closed at $14.77, up 3.29%, and is down 0.10% in pre-market trading.

RDY sentiment & insider activity

Recent RDY coverage spans regulation, earnings and financial news.

What's driving RDY

  • Approval expands RDY's diabetes portfolio in Brazil.

    rttnews.com · Nov 6, 2026

  • Positive regulatory approval in a large emerging market.

    rttnews.com · Nov 5, 2026

  • Approval of a generic HIV preventative could improve RDY's product pipeline and future revenue expectations.

    seekingalpha.com · Nov 3, 2026

  • ICICI Securities reports Dr. Reddy's Laboratories (DRL) Q2FY27 EBITDA and PAT exceeded expectations by 32% and 26%, respectively. US sales grew 9.5% QoQ to $258 million, driven by new launches. Management expects double-digit revenue growth and gross margins of 50-55%. They aim for 25% EBITDA margins in the next few years, supported by upcoming catalysts like semaglutide relaunch and biosimilar approvals.

    tradingview.com · Oct 26, 2026

  • Earnings miss may pressure the stock, but upgraded ratings and margin outlook provide upside potential.

    zeebiz.com · Oct 26, 2026

AlphAI scores every news story that mentions RDY with an AI model for sentiment and relevance, and aggregates insider trades from DR REDDYS LABORATORIES LTD's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $RDY

Score

Weekly Buzz: RDY, LUPIN, SUNPHARMA Score FDA Wins; AGIO, RARE Slash Jobs; CVS Plots Split

Dr. Reddy's (RDY) secured Brazil approval for generic semaglutide and tentative FDA approval for an HIV prevention shot. Lupin (LUPIN.NS) and Sun Pharma (SUNPHARMA.NS) received FDA approvals for generic Firdapse and Ilumya. Agios (AGIO) and Ultragenyx (RARE) announced significant job cuts. CVS (CVS) plans to split into two publicly traded companies. Teva (TEVA) expanded its biosimilars portfolio through a deal with Samsung Bioepis.

Dr.Reddy's Wins Brazil Approval For Generic Ozempic Alternative

Dr. Reddy's Laboratories (RDY) received approval from Brazil's ANVISA for its generic semaglutide injection, a diabetes treatment similar to Novo Nordisk's Ozempic. The product will be marketed in Brazil, a key market with 16.6 million diabetes patients and a $244.6 million semaglutide market. RDY plans to launch the product via a partnership with Ache. RDY stock closed at $14.77, up 3.29%, and is down 0.10% in pre-market trading.

Buy Dr Reddys Laboratories: target of Rs 1430: ICICI Securities

ICICI Securities reports Dr. Reddy's Laboratories (DRL) Q2FY27 EBITDA and PAT exceeded expectations by 32% and 26%, respectively. US sales grew 9.5% QoQ to $258 million, driven by new launches. Management expects double-digit revenue growth and gross margins of 50-55%. They aim for 25% EBITDA margins in the next few years, supported by upcoming catalysts like semaglutide relaunch and biosimilar approvals.

Jefferies upgrades Dr. Reddy’s stock rating on margin outlook

Jefferies upgraded Dr. Reddy’s Laboratories (RDY) from Underperform to Hold, raising its price target to INR1,320.00. The firm cited a 15% Ebitda beat in Q3, strong margins, and improved earnings estimates. Dr. Reddy’s reported $905M in revenue, slightly above forecasts, with improved margins. The company expects to resume Semaglutide supplies and U.S. approval for bAbatacept in late 2026.

$RDYHighEarnings

DR REDDYS LABORATORIES LTD (RDY): Financial results for H1 2027

DR REDDYS LABORATORIES LTD (RDY) furnished an SEC Form 6-K — earnings release. Exhibit 99.2 CONTACT DR. REDDY’S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. Investor relationS Media relationS AISHWARYA SITHARAM SANTOSH VYAS aishwaryasitharam@drreddys.com santoshvyas@drreddys.com Dr. Reddy’s Q2 & H1FY27 Financia

Dr. Reddy's Laboratories Profit Drops In Q2

Dr. Reddy's Laboratories reported a 36% drop in Q2 profit to INR 9,134 million, or INR 11.10 per share, from the prior year. Revenue declined to INR 86,708 million, driven by lower lenalidomide sales in North America. Pre-market trading showed a 0.76% increase to $13.32 on the NYSE.

Related tickers